Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | J9039 |
Short Description | Injection, blinatumomab |
Long Description | Injection, blinatumomab, 1 microgram |
Pricing indicator | 51 |
Coverage code | C |
ASC payment group code | YY |
BETOS2 code | O1D |
Action code | N |
Type of service | 1 |
Effective date | 2016-01-01 |
Date Added | 2016-01-01 |
HCPCS/NDC Cross-Walk
NDC | HCPC | Description | Drug Name | Labeler Name | HCPCS Dosage | PKG Size | PKG QTY | Bill Units | Bill Units PKG |
---|---|---|---|---|---|---|---|---|---|
55513016001 | J9039 | Injection, blinatumomab | BLINCYTO | AMGEN USA, INC. | 1 MCG | 1 | 1 | 35 | 35 |
HCPCS Billing Calculator
Dosage given to patient (per dose) | |
---|---|
HCPCS Dosage | 1 MCG |
HCPCS/CPT Billing Units | 1 |
Total doses ordered | |
Billing Units | 1 |
Drug Details
-
Blinatumomab is used in adults and children to treat certain types of acute lymphocytic leukemia (ALL; a type of cancer of the white blood cells) that has not gotten better, or that has returned after treatment with other medications. Blinatumomab is also used in adults and children to treat ALL that is in remission (a decrease or disappearance of signs and symptoms of cancer), but some evidence of the cancer remains. Blinatumomab is in a class of medications called bispecific T-cell engager antibodies. It works by slowing or stopping the growth of cancer cells in your body.